Nitin Kumar Sharma’s Post

🚀 Exciting news from Celltrion! 🚀 Celltrion Inc has successfully secured bids to supply three key biopharmaceutical products #Remsima (infliximab), #Herzuma (trastuzumab), and #Vegzelma (bevacizumab) to UniHA, France's largest pharmaceutical procurement group. These biosimilars treat #autoimmunediseases, #breastandgastriccancer, #colorectalcancer, and #nonsmallcelllungcancer. #UniHA controls significant market shares: 30% infliximab, 27% bevacizumab, and 13% trastuzumab. As a result, Celltrion will be the exclusive supplier of these products until June 2027. Additionally, through the #Bretagneprocurementgroup, Celltrion will supply #Herzuma and #Vegzelma until June 2028. Celltrion’s strategy focused on strong relationships with key stakeholders, ESG achievements, and supply stability. The company's #RemsimaSC has also captured a 26% market share, contributing to a combined 76% share for the #Remsima line in France. Looking ahead, Celltrion plans to expand its participation in the French bidding market and strengthen its sales capabilities for newly approved products like #Omviclone (omalizumab) and #CT-P43 (ustekinumab). The company will aggressively participate in upcoming bids and strive for outstanding results to ensure more patients benefit from Celltrion's treatments. #Celltrion #Pharmaceuticals #Biosimilars #Healthcare #Innovation #France #UniHA #Bretagne #Remsima #Herzuma #Vegzelma #Omviclone #CTP43 #Infliximab #Trastuzumab #Bevacizumab #Omalizumab #Ustekinumab #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification For Detailed News: https://lnkd.in/d94c3p4T Follow our page for more industry updates: https://lnkd.in/de5zNWmK

Hi. It's getting very hot in Japan. We've posted a new blog article regarding the sales highlight of Japan's drug market in 2023 as follows: https://lnkd.in/gpFYRYDc We are a part of ELIQUENT Life Sciences that creates an unprecedented assembly of global regulatory leaders, industry experts, and technical specialists - brought together to bridge the spectrum of regulatory challenges across the product lifecycle. The collective capabilities of the united ELIQUENT team enable a comprehensive approach that delivers integrated solutions to support pharmaceutical, biotechnology, medical device, and combination product companies navigating the complex global regulatory landscape. Top Performing Products: Keytruda (Pembrolizumab) reclaimed the top sales position, surpassing Opdivo (Nivolumab), which experienced a 4.2% revenue decline in Q1 2024 due to a 15% price cut in April. Oncology Market Dominance: The oncology market grew by 9.8% to nearly 2 trillion yen, representing 17% of the domestic market. Keytruda led with a 22.5% increase to 164.8 billion yen. Opdivo grew by 3.5% to 164.5 billion yen but fell to second place due to market recalculation impacts. Imfinzi (Durvalumab) posted a 116% growth, reaching 120.7 billion yen, following new cancer indications. Significant Growth in the Following Therapeutic Areas.......

📢Exciting News 📍 Today, Accord Biopharma, Inc. a subsidiary of Intas Pharmaceutical Ltd has gotten the acceptance of its #Biosimilar DMB-3115 which is proposed biosimilar to STELARA ® (ustekinumab) from #USFDA 📌Accord Biopharma, Inc. conducted multi-regional Phase-III clinical trail in patients with plaque psoriasis. The main focus of the study was the rate of change in the Psoriasis Area and Severity Index (PASI) to assess skin symptom improvement. 💊 STELARA®, a Janssen Biotech blockbuster, approved for psoriasis, psoriatic arthritis, Crohn's, and colitis. It raked in $13.9B in U.S. sales in 2022, ranking among top biologics. #Biosimilar #USFDA #ustekinumab #accordbiopharma #Intas https://lnkd.in/eQiVMPst

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalPharmaceuticalMarket #SmallLymphocyticLymphoma #DrugDevelopment #HealthcareInnovation #PatientCare #MedicalResearch #PharmaceuticalIndustry #HealthcareSettings #TreatmentOptions #MedicalAdvancements

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalChronicLiverDiseases #TherapeuticsMarket #ChemotherapyDrugs #TargetedTherapy #Vaccines #AntiviralDrugs #Immunoglobulins #Corticosteroids #HospitalPharmacies #OnlinePharmacies

On Thursday, Biocon announced a patent settlement with Janssen Inc. for its Stelara biosimilar. With this deal, Biocon will be launching its Bmab 1200, a biosimilar referencing Stelara, in February 2025, subject to FDA approval. Biocon's BLA for Bmab 1200 has already been accepted by the FDA for review under the 351(k) pathway. With this agreement, Biocon joins a list of other biosimilar competitors including Amgen, Alvotech/Teva Pharmaceuticals, Samsung Bioepis/Sandoz, Celltrion Inc, Formycon AG/Fresenius Kabi, and Dong-A Pharmaceutical Co.,Ltd/Accord Healthcare, all of whom have launch dates for their respective biosimilar products slated for the first half of 2025. Stelara, introduced in 2009, has been Janssen Inc.'s top-selling drug since 2019, with sales reaching $7 billion in 2023 and is expected to contribute significantly to the company's projected $57 billion revenue by 2025. https://lnkd.in/ddQwnNpq

Pharmaceutical Drug Delivery - 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭(𝟐𝟎𝟐𝟒 - 𝟐𝟎𝟑3) ✅ 𝗚𝗿𝗮𝗯 𝗣𝗗𝗙 𝗙𝗼𝗿 𝗠𝗼𝗿𝗲 𝗗𝗲𝘁𝗮𝗶𝗹𝘀 >>https://lnkd.in/gnaNBQzQ The global pharmaceutical drug delivery market was valued at USD 2.2 billion in 2021 and it is anticipated to grow up to USD 3.3 billion by 2031, at a CAGR of 4.2% during the forecast period. The pharmaceutical drug delivery systems consist of various forms, including controlled-release and oral delivery systems. They can help maximize therapeutic efficacy by controlling drug pharmacokinetics, reducing toxicity, increasing accumulation at the target site, as well as improving patient compliance and acceptance. Recent Developments In June 2022, Gufic Biosciences launched a new drug delivery system: dual-chamber bags at an affordable price in India. In July 2021, Johnson & Johnson received FDA approval for DARZALEX (daratumumab), a subcutaneous formulation that reduces the treatment time for multiple myeloma indications. In December 2020, Pfizer, Inc. received FDA approval for BRAFTOVI (encorafenib) plus combination with cetuximab for the treatment of patients with brafv600e-mutant metastatic colorectal cancer (CRC) who have undergone prior therapy. In November 2020, GlaxoSmithKline plc partnered with IDEAYA to enter the field of Synthetic Lethality, an emerging field in oncology; programs MAT2A, Pol Theta, and Werner Helicase programs, which are part of it, are projected to reach clinical trials in the next three years.

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalTargetedDrugs #ColorectalCancer #PharmaceuticalMarket #CancerTreatment #TargetedTherapies #HospitalCare #SpecialtyClinics #CancerResearch #MedicalAdvancements #PatientCare

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalPrecisionCancerDiagnostics #CancerCare #EarlyDetection #PersonalizedMedicine #AdvancedDiagnostics #HealthcareInnovation #OncologyResearch #PatientOutcomes #MedicalTechnology #CancerTreatment

Technophage, a biopharmaceutical company specializing in the development and production of biologics, particularly bacteriophage-based products, has officially announced the successful dosing of the first patient in this pivotal stage. The trial aims to assess the efficacy of TP-102 in treating diabetic foot ulcers infected by Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii (ID NCT05948592).   This Phase 2b trial is a double-blinded, randomized, placebo-controlled, multicentre study designed to evaluate both the safety and efficacy of TP-102 in patients with Diabetic Foot Infections. Patients will receive a topical application of the investigational product or placebo solution directly on the target ulcer. To be eligible for inclusion, patients must have an infected DFU with at least one target bacterial strain susceptible to TP-102, identified through a culture taken from the target ulcer during the screening visit. The study aims to enroll  80 patients meeting these criteria.   Sofia Côrte-Real, CSO and Deputy CEO of Technophage, expressed satisfaction with the initiation of TP-102 administration, stating, "We are very pleased to effectively start with the administration of TP-102 to patients in need." She further highlighted the company's commitment to delivering innovative medicines to address unmet needs in patient care. Miguel Garcia, the founder and CEO of Technophage, echoed this feeling, emphasizing their anticipation for continued patient enrollment and dosing throughout the trial.   The first patient in this innovative trial was randomized in India. The study is currently in progress in both the United States and India, conducted with approval from the Food and Drug Administration and authorization from the Central Drugs Standard Control Organization, respectively.   #biologics #phagetherapy #technophage  #construirofuturo #PRR